A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab in Patients With nAMD

  • End date
    May 31, 2023
  • participants needed
  • sponsor
    Novartis Pharmaceuticals
Updated on 26 September 2021
Novartis Pharmaceuticals
Primary Contact
Novartis Investigative Site (3.0 mi away) Contact
+65 other location


This study is a prospective, uncontrolled, central registration system, multicenter, domestic observational study (special drug-use surveillance) to evaluate the safety of 52-week clinical treatment with Beovu kit for intravitreal injection in nAMD patients.


The observational period will be 1 year (52 weeks) from the first brolucizumab administration in the primary treated eye.

However, if brolucizumab is discontinued in the primary treated eye and if the treatment is discontinued less than 52 weeks observation period, the observation period will be up to 90 days after the last dose of this drug. This is set in order to collect data as much as possible based on the clinical effect of the drug. If 30 days after the last dose of this drug in a discontinued patient exceeds 52 weeks of the observation period, the patient should be monitored for adverse events until 30 days after the last dose of this drug

Condition Neovascular Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Neovascular Age Related Macular Degeneration
Treatment Beovu
Clinical Study IdentifierNCT04632056
SponsorNovartis Pharmaceuticals
Last Modified on26 September 2021


Yes No Not Sure

Inclusion Criteria

Patients must provide written consent to cooperate in this study before treatment with Beovu kit for intravitreal injection
Patients using Beovu kit for intravitreal injection for the first time for the following indication
Indication: age-related macular degeneration with subfoveal choroidal neovascularization

Exclusion Criteria

Patients with a history of treatment with a drug containing the same ingredient (brolucizumab; investigational drug or post-marketing clinical study drug) as Beovu kit for intravitreal injection
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note